Hundreds of thousands of lives could be saved annually by treating patients with acute high pressure in the lung blood circulation with Supernitro.
Acute pulmonary hypertension, high pressure in the lung blood circulation, is a life-threatening condition where the lung blood vessels suddenly constrict, making the right part of the heart unable to pump the blood through the lungs.
The method currently used in an effort to treat the life-threatening condition is to let the patient inhale nitric oxide gas. But this method has major shortcomings. This is where Supernitro comes in with its unique and efficient properties.
Attgeno AB, home of Supernitro, is a Swedish pharmaceutical company founded to develop and commercialize the discovery of completely new methods to provide innovative and efficient nitric oxide-donating drugs.